Myeloma stem cells are believed to cause the growth of multiple myeloma. Many myeloma treatments kill the myeloma plasma cells, but according to William Matsui, MD of the Johns Hopkins Kimmel Cancer Center, these treatments may not affect the myeloma stem cells. Dr. Matsui recently presented results from a study he did with colleagues at Johns Hopkins testing a new monoclonal antibody with lenalidomide and dex. Just with len/dex, he saw myeloma stem cells increase by 2.5 times, but when the new monoclonal antibody was added, it decreased the myeloma stem cells by half. Learn more about this up and coming new target in clinical trials that can kill myeloma cells at their source.